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Background: Tuberculous meningitis (TBM) is the most severe form of tuberculosis and
results in high morbidity and mortality in children. Diagnostic delay contributes to the
poor outcome. There is an urgent need for new tools for the rapid diagnosis of TBM,
especially in children.
Methods: We collected serum samples from children in whom TBM was suspected
at a tertiary hospital in Cape Town, South Africa. Children were subsequently classified
as having TBM or no TBM using a published uniform research case-definition. Using
a multiplex cytokine array platform, we investigated the concentrations of serum
biomarkers comprising biomarkers that were previously found to be of value in the
diagnosis of adult pulmonary TB (CRP, SAA, CFH, IFN-γ, IP-10, Apo-AI, and transthyretin)
plus other potentially useful host biomarkers as diagnostic candidates for TBM.
Findings: Out of 47 children included in the study, 23 (48.9%) had a final diagnosis of
TBM and six were HIV infected. A modified version of the adult 7-marker biosignature
in which transthyretin was replaced by NCAM1, diagnosed TBM in children with AUC of
0.80 (95% CI, 0.67–0.92), sensitivity of 73.9% (95% CI, 51.6–89.8%) and specificity of
66.7% (95% CI, 44.7–84.4%), with the other six proteins in the signature (CRP, IFN-γ,
IP-10, CFH, Apo-A1, and SAA) only achieving and AUC of 0.75 (95%CI, 0.61–0.90) when
used in combination. A new childhood TBM specific 3-marker biosignature (adipsin,
Aβ42, and IL-10) showed potential in the diagnosis of TBM, with AUC of 0.84 (95%
CI, 0.73–0.96), sensitivity of 82.6% (95 CI, 61.2–95.0%) and specificity of 75.0% (95%
CI, 53.3–90.2%) after leave-one-out cross validation.
Conclusion: A previously described adult 7-marker serum protein biosignature showed
potential in the diagnosis of TBM in children. However, a smaller childhood TBM-specific
3-marker signature demonstrated improved performance characteristics. Our data
indicates that blood-based biomarkers may be useful in the diagnosis of childhood TBM
and requires further validation in larger cohort studies.
Keywords: tuberculosis, meningitis, biomarker, sensitivity and specificity, diagnosis, early diagnosis, immunologic
tests, child
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INTRODUCTION
Globally, tuberculosis (TB) is currently one of the top 9 causes
of death, ranking above HIV and malaria (1). According to
the World Health Organisation (WHO) 2018 TB report, 10%
of all reported TB cases in 2017 were in children (2), and 230
000 children died from TB (1). About 20–25% of pediatric TB
cases are extra pulmonary TB (EPTB), including tuberculous
meningitis (TBM) (3). In a clinical and laboratory surveillance
study over a 1 year period in theWestern Cape Province of South
Africa almost one-fifth of children with TB had a disseminated
form (TB meningitis or miliary TB) (4).
TBM is a central nervous system infection caused by
Mycobacterium tuberculosis (M. tb) and it is the most severe
form of tuberculosis, with high morbidity and mortality (5, 6).
The rate of TBM is higher among children than adults (7). A
study in South Africa reported that TBM is the most common
form of bacterial meningitis among children (8). Outcomes of
TBM in children include death in up to 50% of cases and
neurological sequelae in up to 53.9% of survivors (9, 10). The
poor outcomes of TBM are mainly due to delayed diagnosis and
late initiation of anti-tuberculosis therapy (11). The improvement
of case detection and early administration of curative treatment
are key in the management of pediatric tuberculosis (12).
However, the diagnosis of TBM in children is challenging,
due to sub-optimal performance of the currently available
laboratory diagnostic methods. Smear microscopy remains the
most widely used test for bacteriological confirmation of TB in
clinical specimens, particularly in resource-constrained settings
(13). Smear microscopy has poor sensitivity of about 10–20%
in diagnosing TBM (9). Although M. tb culture, the gold
standard test for diagnosing TB disease has a relatively high
sensitivity (60–70%) for diagnosing TBM in comparison to
smear microscopy, its turnaround time is up to 42 days (9).
Furthermore, culture is expensive, prone to contamination and
requires extensive laboratory infrastructure, which is not often
available in resource-constrained settings (14). The GeneXpert
MTB/RIF test R©, arguably the most important recent advance
in TB diagnosis, yields results within 2 h and detects resistance
to rifampicin as a proxy for the presence of MDR strains.
However, GeneXpert has several well-publicized shortcomings
including low negative predictive value, cost effectiveness and the
requirement for technical infrastructure (13, 15).
The GeneXpert cannot exclude TBM due to its imperfect
sensitivity and negative predictive value (16). A study conducted
in Uganda reported sensitivity of 28% when using 2mL of
uncentrifuged CSF, and the sensitivity improved to 72% when a
large volume (6mL) of centrifuged CSF was used (17), suggesting
that high volumes of CSF are required to obtain a positive TBM
diagnosis using Xpert. The GeneXpert Ultra has been shown to
overcome some of the shortcomings of GeneXpert MTB/RIF as
it showed improved sensitivity of 95% and negative predictive
value of 99% in a more recent study on HIV positive adults with
TBM (16). However, there are concerns over lowered specificity
and positive predictive value compared to GeneXpert MTB/RIF,
which require prospective testing in a large population including
children and those that are HIV-uninfected (16, 18, 19). Themain
common limitation to the above-described tests is the difficulty in
obtaining the diagnostic sample (CSF).
The diagnosis of TBM is mostly based on a combination of
suggestive clinical findings, multiple suggestive laboratory tests
on the CSF, supportive features on brain imaging findings and the
exclusion of other possible causes of meningitis. These criteria
are unreliable as individual tests, and often require referral of
children to tertiary healthcare facilities for the performance of
advanced testing, due to the unavailability of most of the relevant
techniques in primary and secondary healthcare facilities, leading
to further delays in the initiation of treatment (20). Consequently,
children seen at primary and secondary healthcare facilities
often have multiple missed opportunities; up to six visits before
eventual diagnosis of TBM is made (20). There is an urgent need
for new TBM diagnostic tools suitable for use in children at the
point of care or bedside.
Host biomarker-based tests may be valuable in the diagnosis
of TBM as they have previously been shown to be potentially
useful in other extrapulmonary forms of TB (21), and may be
easily converted into point-of-care or bedside tests (22, 23).
Most studies investigating host biomarkers for diagnosis of
neurological disorders have focused on CSF as a biological
specimen from the site of infection (24), including in the
diagnosis of TBM (25, 26). Despite the potential of CSF-based
host biomarkers in the diagnosis of TBM, the collection of CSF
requires lumbar puncture, an invasive procedure which requires
special skill and training and might not be readily available,
leading to delay in diagnosis.
As several studies have shown the potential of blood-based
host protein biomarkers in the diagnosis of TB disease, albeit
mostly adult pulmonary TB-based studies thus far (27, 28), we
hypothesized that blood-based host protein biosignatures may
be useful in the diagnosis of TBM in children. The aim of the
present study was to ascertain whether host biomarkers that have
shown potential in the diagnosis of adult pulmonary TB in serum
and plasma samples (27, 28) possessed diagnostic potential for
childhood TBM. We were specifically interested in evaluating
the performance of a previously established adult seven-marker
serum protein biosignature (CRP, transthyretin, IFN-γ, CFH,
Apo-AI, IP-10, and SAA) (28) as a tool for the diagnosis of
childhood TBM, and to also evaluate the potential of other
host biomarkers.
MATERIALS AND METHODS
Study Participants
Participants enrolled into the present study were children who
presented with signs and symptoms suggestive of meningitis and
requiring CSF examination for routine diagnostic purposes at
the Tygerberg Academic Hospital in Cape Town, South Africa
between November 2016 and November 2017 as previously
described (29). Children were eligible for participation in the
study if they were between the ages of 3 months and 13 years,
provided that written informed consent was obtained from the
parents or legal guardians. Assent was obtained from children
older than 7 years if they had a normal level of consciousness i.e.,
a Glasgow Coma Score (GCS) of 15/15. The study was approved
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by the Health Research Ethics Committee of the University of
Stellenbosch, Tygerberg Academic Hospital, and the Western
Cape Provincial Government.
After collection of specimens for routine diagnostic purposes,
an additional 1ml of blood was collected into a BD Vacutainer R©
serum tube and processed within an average of 2 h from
collection, for the purposes of the present study. Blood samples
were centrifuged at 1,200 × g for 10min, followed by aliquoting
of serum and storage at−80◦C until analyzed.
Diagnostic Assessment
As previously described (29), a comprehensive clinical
examination was performed on all patients by a specialist
pediatric neurologist. Following routine clinical investigations,
computed tomography (CT) of the brain, air-encephalography,
and magnetic resonance (MR) imaging were performed
as clinically indicated. CSF was obtained through lumbar
puncture and investigations including appearance and color
determination, differential cell counts, CSF protein, and glucose
levels were done. After CSF centrifugation, the following
procedures were done: Gram staining, India ink examination,
culture of the centrifuged sediment on blood agar plates (for
pyogenic bacteria), Auramine “O” staining and fluorescence
microscopy, culture using the mycobacterium growth indicator
tubes (MGIT)TM (Becton and Dickinson) and examination for
M. tb DNA using the HAIN Genotype MTBDRplus kit (Hain
Life science GmbH, Germany). Other routinely investigated
parameters including serum glucose level and viral PCR were
done. All data generated from the study were recorded in a study
specific REDCap web-based database.
Classification of Study Participants
Patients were classified as probable or definite TBM according
to a uniform research case definition (30) based on a scoring
system consisting of clinical criteria, CSF criteria, cerebral
imaging criteria, evidence of extraneural TB and exclusion of
alternative diagnoses. TBM was classified as “probable” when
patients scored ≥12 when neuroimaging was available and ≥10
when neuroimaging was unavailable. Following the definition
by Marais et al. (30), a diagnosis of definite TBM was made
if there was detection of the M. tb bacilli in the CSF by one
of the following tests: acid-fast bacilli, culture, or nucleic acid
amplification tests (NAATs). For the purposes of this study,
the TBM group included probable TBM and definite TBM,
whereas the no-TBM group included children with other types
of meningitis including bacterial and viral meningitis, and a
wide range of other diagnoses as mentioned in Table 1 and also
previously reported (29).
Immunoassays
We evaluated the concentrations of biomarkers assessed in
our previous study (29) in serum samples obtained from
the same study participants. As reported in our previous
study, the concentrations of 69 host biomarkers including
six of the proteins comprising the previously established
adult seven-marker serum protein biosignature (CRP, SAA,
complement factor H, IFN-γ, IP-10, and Apo AI) (28), were
evaluated by ELISA (cathelicidin LL-37) or using the Luminex
platform (all other biomarkers). Transthyretin, one of the
biomarkers comprising the previously established adult seven-
marker signature was not assessed due to discontinued supply
from the manufacturer.
Serum cathelicidin LL-37 levels were evaluated using an
ELISA kit purchased from Elabscience Biotechnology Inc.
(Catalog #E-EL-H2438). Experiments were done according to the
procedure recommended by themanufacturer after which optical
densities (OD) were read at 450 nm by an automated microplate
reader (iMarkTM Microplate Reader, Bio Rad Laboratories). The
mean OD of the blank wells was subtracted from the OD of
the sample wells and the background-corrected ODs used for
statistical analysis.
Serum levels of CCL1(I-309), CCL2(MCP-1), CCL3(MIP-
1α), CCL4(MIP-1β), CD40 ligand (CD40L), CXCL8(IL-8),
CXCL9(MIG), CXCL10(IP-10), granulocyte colony-stimulating
factor (G-CSF), granulocyte-macrophage colony-stimulating
factor(GM-CSF), interferon (IFN)-γ, interleukin (IL)-1β,
IL-10, IL-12/23(p40), IL-17A, IL-13, IL-21, IL-4, IL-6, IL-7,
matrix metalloproteinase (MMP)-1, MMP-8, transforming
growth factor (TGF)-α, tumor necrosis factor (TNF)-α,
soluble neural cell adhesion molecule (sNCAM-1/CD56),
MMP-7, VEGF-A, ferritin and MMP-9 were assessed in
Luminex kits purchased from R&D Systems Inc. (Bio-Techne),
Minneapolis, USA wherease those of apolipoprotein (Apo)-AI,
Apo-CIII, complement C3, complement factor H, BDNF,
cathepsin D, soluble intracellular adhesion molecule (sICAM)-
1, myeloperoxidase (MPO), platelet derived growth factor
(PDGF)-AA, CCL5(RANTES), PDGF-AB/BB, soluble vascular
adhesion molecule (sVCAM-1), plasminogen activator inhibitor
(PAI)-1(total), S100 calcium-binding protein B (S100B), amyloid
beta 1–40 (Ab40), Ab42, soluble receptor for advanced glycation
end products (sRAGE), Glial cell-derived neurotrophic factor
(GDNF), C reactive protein (CRP), alpha-2-antitrypsin (A1AT),
pigment epithelium-derived factor (PEDF), serum amyloid P
(SAP), CCL18(MIP-4/PARC), complement C4 (CC4), CC2,
CC4b, CC5, CC5a, CC9, complement factor D (adipsin/CFD),
mannose binding lectin (MBL), complement factor 1 (CF1), sP-
selectin, von Willebrand factor-cleaving protease (ADAMTS13),
D-DIMER, growth differentiation factor (GDF)-15, myoglobin,
lipocalin2 (NGAL), and serum amyloid A (SAA) were evaluated
in kits purchased form Merck Millipore, Billerica, MA, USA.
All biomarkers were evaluated following the instructions
of the respective kit manufacturers (R&D Systems and Merck
Millipore, respectively) in a blinded manner. All experiments
were performed on the Bio Plex platform (Bio Rad Laboratories,
Hercules, USA) in an ISO15189 accredited laboratory. Data
acquisition and analysis of median fluorescent intensity was
done using the Bio Plex Manager Version 6.1 software (Bio
Rad Laboratories). The values of analytes in the quality
control reagents evaluated with the samples were within their
expected ranges.
Statistical Analysis
Data were analyzed using Statistica (TIBCO Software Inc.,
CA, USA), and GraphPad Prism version 6 (Graphpad
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TABLE 1 | Clinical and demographic characteristics of children included in the study.
All, No.
(%)
Definite TBM, No.
(%)
Non-confirmed TBM,
No. (%)
All TBM,
No. (%)
No-TBM#,
No. (%)
Number of participants 47 3 (6.4) 20 (42.6) 23 (48.9) 24 (51.1)
Median age in months (IQR) 22.0 (10.5–57.0) 58.0 (36.5–101.5) 17.5 (10.3–31.5) 18.0 (11.0–40.0) 30.0 (9.0–96.0)
Males, n (%) 30 (63.8) 1 (33.3) 12 (60.0) 13 (56.5) 17 (70.8)
HIV Positive, n/no tested 6 /37 0/2 0/19 0/21 6 /15
BCG done, n (%) 33 (70.2) 0 (0.0) 16 (80.0) 17 (73.9) 16 (66.7)
TB contact in history 14 (29.8) 0 (0.0) 7 (35.0) 7 (30.4) 7 (29.2)
Presenting symptoms
Fever 17 (36.2) 2 (66.7) 7 (35.0) 10 (43.5) 7 (29.2)
Vomiting 12 (25.5) 0 (0.0) 6 (30.0) 7 (30.4) 5 (20.8)
Weight loss 10 (21.3) 1 (33.3) 6 (30.0) 7 (30.4) 3 (12.5)
Seizures 18 (38.3) 1 (33.3) 9 (45.0) 9 (39.1) 9 (37.5)
Cough 16 (34.0) 1 (33.3) 6 (30.0) 9 (39.1) 7 (29.2)
Altered consciousness 13 (27.7) 1 (33.3) 6 (30.0) 6 (26.1) 7 (29.2)
Symptom duration, days 15.0 18.5 25.8 9.4 5.6
Clinical signs
Raised intracranial pressure 10 (21.3) 1 (33.3) 5 (25.0) 5 (21.7) 5 (20.8)
Hemiplegia 13 (27.7) 1 (33.3) 9 (45.0) 7 (30.4) 6 (25.0)
#The no-TBM group included children with bacterial meningitis (n = 2), viral meningitis (n = 2), asphyxia (n = 1), autoimmune encephalitis (n = 1), febrile seizure (n = 3), Guilain Barre
(n = 1), HIV encephalopathy (n = 1), focal seizures (n = 1), leukemia (n = 1), Miliary TB (With lymyphocytic interstitial pneumonitis) (n = 1), Developmental delay (n = 1), Breakthrough
seizure (n = 1), Gastroenteritis (Caused by shock) (n = 1), Idiopathic intracranial hypertention (IIH) (n = 1), Viral Gastroenteritis (Adeno and Rota) and encephalopathy (n = 1), Stroke (n =
1), Mitochondrial diagnosis (n = 1), viral pneumonia (This included also SAM and nosocomial sepsis) (n = 1), Febrile Seizure and Acute gastroenteritis (n = 1) and other (n = 1). Adapted
and modified from Manyelo et al. (29). TBM, Tuberculous Meningitis; BCG, Bacille Calmette-Guérin; IQR, Interquartile range; CSF, Cerebrospinal fluid; HIV, Human immunodeficiency
virus. Unless otherwise stated, n = 47.
software, CA, USA). The Mann Whitney U test was used
to compare the differences in the concentrations of host
biomarkers between the TBM and the no-TBM groups.
The receiver operator characteristics (ROC) curve analysis
procedure was used to assess the diagnostic accuracy of
individual host biomarkers for TBM. Optimal cut-off values
and associated sensitivities and specificities were selected
based on the Youden’s index (31). The utility of combinations
of biomarkers in the diagnosis of TBM was ascertained by
general discriminant analysis (GDA), followed by leave-one-
out cross validation. Data were log-transformed to prior
to GDA.
RESULTS
A total of 47 children who presented with signs and symptoms
strongly suggestive of TBM were included in the study, 30
(63.8%) of whom were males (Figure 1). The mean age of all the
children was 22months (interquartile range: 10.5–57) and six out
of 37 with known HIV status (16.2%) were HIV infected. Bacillus
Calmette–Guérin (BCG) vaccination is routinely administered
in the high TB burdened setting where study participants were
recruited. Out of the 47 study participants, 33 (70.2%) had
documented evidence of BCG vaccination. The performance
of the biomarkers was assessed regardless of BCG vaccination
status. Using a composite reference standard based on a
uniform research case definition of TBM (30), 23 of the
children were diagnosed with definite (n = 3) or probable
(n = 20) TBM. The 24 children without TBM included
children with bacterial meningitis (n = 2), viral meningitis
(n = 2), and children with other diagnoses as described
in Tables 1, 2.
Application of the Previously Established
Adult 7-Marker Serum Protein Biosignature
in the Diagnosis of TBM in Children
We aimed to assess the performance of the previously described
adult pulmonary TB seven-marker (CRP, IFN-γ, IP-10, CFH,
Apo-A1, SAA and transthyretin) in the diagnosis of TBM in
children. However, one of the key biomarkers comprising the 7-
marker serum biosignature, transthyretin, was not available due
to discontinued supply from the reagent manufacture (Merck).
When the concentrations of the six available markers (CRP, IFN-
γ, IP-10, CFH, Apo-A1, and SAA), from the adult pulmonary
TB seven-marker signature (28) were evaluated in serum samples
from children with TBM vs. those without TBM individually,
significant differences were obtained for CFH only. After ROC
curve analysis, the most useful individual marker from this
signature, as determined by AUC was CFH (Table 3). When
used in combination, the AUC for this 6-marker model in the
diagnosis of TBMwas 0.75 (95%CI, 0.61–0.90); corresponding to
sensitivity of 69.6% (95%CI, 47.1–86.8%) and specificity of 62.5%
(95% CI, 40.6–81.2%). After leave-one-out cross validation, the
6-marker combination diagnosed TBM with sensitivity of 65.2%
(95% CI, 42.7–83.6%) and specificity of 54.2% (95% CI, 32.8–
74.5%). When transthyretin was replaced by NCAM1, another
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TABLE 2 | Overview of scoring criteria in children with “definite,” “probable,” and “no” TBM.
Definite TBM n/N (%) Probable TBM n/N (%) No TBM n/N (%)
Total number 3 20 24
Symptom duration > 5 days 1/3 (33) 13/20 (65) 7/24 (29)
≥1 week of: weight loss/poor weight gain, night sweats or persistent
cough >2 weeks
1/3 (33) 9/20 (45) 3/24 (13)
History of recent TB contact or positive TST or IGRA 0/3 (0) 9/20 (45) 5/24 (21)
Focal neurological deficit 1/3 (33) 8/20 (40) 4/24 (17)
Cranial nerve palsy 1/3 (33) 8/20 (40) 0/24 (0)
Altered consciousness 1/3 (33) 8/20 (40) 4/24 (17)
CSF clear 3/3 (100) 20/20 (100) 20/24 (83)
CSF cells: 10–500 per µl 3/3 (100) 15/20 (75) 1/24 (4)
CSF lymphocyte predominance (>50%) 3/3 (100) 14/20 (70) 8/24 (33)
CSF protein concentration >1 g/L 3/3 (100) 13/20 (65) 3/24 (13)
CSF:serum glucose ratio <50% and/or CSF glucose concentration
<2.2 mmol/L
2/3 (67) 9/20 (45) 3/24 (13)
Hydrocephalus (CT and/or MRI) 2/3 (67) 16/20 (80) 1/24 (4)
Basal meningeal enhancement (CT and/or MRI) 1/3 (33) 16/20 (80)) 0/24 (0)
Tuberculoma (CT and/or MRI) 0/3 (0) 4/20 (20) 0/24 (0)
Infarct (CT and/or MRI) 2/3 (67) 8/20 (40) 3/24 (13)
Pre-contrast basal hyperdensity (CT) 1/3 (33) 6/20 (30) 0/24 (0)
CXR suggestive of active TB 2/3 (67) 8/20 (40) 7/24 (29)
CXR suggestive miliary TB 0/3 (0) 5/20 (25) 2/24 (8)
Extraneural radiological TB 0/3 (0) 0/20 (0) 0/24 (0)
Extraneural M. tuberculosis confirmation 1/3 (33) 6/20 (30) 4/24 (17)
TBM, tuberculous meningitis; BM= bacterial meningitis; TB, tuberculosis; TST, tuberculin skin test; IGRA, interferon gamma-release assay; CSF, cerebrospinal fluid; gluc, glucose; CT,
computed tomography; MRI, magnetic resonance imaging; CXR, chest radiograph. Unless otherwise stated, n = 47.
candidate biomarker that showed potential in a previous adult
study (27), the modified 7-marker biosignature (CRP, IFN-γ,
IP-10, CFH, Apo-A1, SAA, and NCAM1) diagnosed TBM with
improved AUC of 0.80 (95% CI, 0.67–0.92); corresponding to
sensitivity of 73.9% (95% CI, 51.6–89.8%) and specificity of
66.7% (95%CI, 44.7–84.4%) (Figure 2). After leave-one-out cross
validation, the modified 7-marker biosignature diagnosed TBM
with sensitivity of 60.9% (95% CI, 38.5–80.3%) and specificity
of 58.3% (95% CI, 36.6–77.9%), with positive and negative
predictive values of 58.3% (95% CI, 44.1–71.4) and 60.9% (95%
CI, 45.8–74.1), respectively.
Utility of All Individual Host Serum Protein
Biomarkers in the Diagnosis of TBM
When the concentrations of all individual host biomarkers
(total of 69) evaluated in this study were compared between
children with and those without TBM, regardless of whether
they were part of the adult 7-marker signature or not, using
the Mann Whitney U test, the median levels of 16 including
sVCAM-1, CCL2, IL-4, TNF-α, CCL4, adipsin, SAP, CC5, G-
CSF, IL-10, Apo-CIII, IL-17A, PAI-1, PDGF AB/BB, MBL,
and NCAM-1 were significantly different (p < 0.05) between
the two groups, with differences in the concentrations of
five markers (CC4b, MMP-1, CXCL8, CC4, sRAGE) showing
trends for differences between the two groups (0.05 < p
≤ 0.09). The concentrations of SAP, CC5, Apo-CIII, PAI-1,
PDGF-AB/BB, and MBL were significantly higher in samples
from children with TBM whereas those of sVCAM-1, CCL2,
IL-4, TNF-α, CCL4, adipsin, G-CSF, IL-10, IL-17A, and
NCAM-1 were higher in samples from children without TBM
(Supplementary Table 1). When the diagnostic potentials of
individual serum biomarkers were assessed by ROC curve
analysis, 13 of these markers showed promise as ascertained by
AUC≥ 0.70 (Supplementary Table 1, Figure 3).When onlyHIV
negative children were considered, there were improvements in
the performances of other host markers including MMP-1 and
IL-7 whereas median levels of six including IL-10, MBL, sRAGE,
CC4, CC4b, and NCAM-1 were no longer significantly different
(Data not shown).
Identification of a New 3-Marker Signature
for the Diagnosis of TBM
When the data obtained from all study participants were fitted
into the General Discriminant Analysis (GDA)models regardless
of HIV status and regardless of whether biomarkers were part of
the adult 7-marker signature or not, optimal prediction of TBM
was shown to be achieved with a combination of three markers.
The most accurate three-marker biosignature comprising of
adipsin, Aβ42 and IL-10 diagnosed TBM with AUC of 0.84
(95% CI, 0.73–0.96); corresponding to a sensitivity of 82.6%
(95% CI, 61.2–95.0%) and specificity of 75.0% (95% CI, 53.3–
90.2%) (Figure 4). After leave-one-out cross validation, there
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FIGURE 1 | Flow chart showing the study design and classification of study participants. CRF, case report form; TBM, Tuberculous meningitis; No-TBM, Individuals
presenting with symptoms and investigated for TB but TBM ruled out. The No TBM group included bacterial meningitis (n = 2), viral meningitis (n = 2) and children
with other diagnoses (Table 1). Adapted from Manyelo et al. (29).
was no change in the sensitivity of the 3-marker biosignature,
whereas the specificity dropped to 70.8% (95 CI, 48.9–87.4%).
The positive and negative predictive values of the biosignature
were 73.1% (95% CI, 58.6–83.9) and 81.0% (95% CI, 62.7–
91.5), respectively after leave-one-out cross validation. Further
optimization of the biosignature through the selection of
better cut-off values yielded both improved sensitivity and
specificity of 83%.
Differential Expression of Host Biomarkers
in Serum, Compared to CSF
Considering that all biomarkers evaluated in the current
study were previously evaluated in CSF samples from the
same children (29), we compared expression of these proteins
between CSF and serum. We observed that the levels of 18
proteins including Aβ40, Aβ42, MIP-1α, IL-8, IFN-γ, IL-10,
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TABLE 3 | Usefulness of analytes comprising the previously established adult 7-marker serum protein biosignature in the diagnosis of TBM in children.
Markers Median in TBM (IQR) Median in Non-TBM
(IQR)
p-value AUC (95%
CI)
Cut-off value Sensitivity %
(95% CI)
Specificity %
(95% CI)
#CFH 415846.5
(363515.9–470137.5)
314294.0
(261691.8–412727.7)
0.009719 0.72
(0.57–0.87)
>350185.0 87.0
(66.4–97.2)
66.7
(44.7–84.4)
NCAM1 246692.5
(164329.5–305706.5)
285446.4
(256271.6–342048.0)
0.036064 0.68
(0.52–0.84)
<264419.0 69.6
(47.1–86.8)
70.8
(48.9–87.4)
#Apo AI 302283.6
(267898.0–346446.2)
286350.3
(191698.6–320139.9)
0.160089 0.62
(0.46–0.78)
>287512.0 65.2
(42.7–83.6)
54.2
(32.8–74.5)
CXCL10/IP-10 55.9 (35.9–169.1) 75.8 (49.3–298.3) 0.213146 0.61
(0.44–0.77)
<57.2 52.2
(30.6–73.2)
66.7
(44.7–84.4)
#CRP 230000.0
(230000.0–230000.0)
230000.0
(63731.2–230000.0)
0.380342 0.56
(0.43–0.69)
>80721.0 87.0
(66.4–97.2)
33.3
(15.6–55.3)
#SAA 65700.0
(847.0–230000.0)
39439.7
(6551.9–226031.8)
0.656243 0.54
(0.37–0.71)
>59894.0 56.5
(34.5–76.8)
66.7
(44.7–84.4)
IFN-γ 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.928917 0.51
(0.39–0.63)
<61.5 87.0
(66.4–92.2)
20.8
(7.1–42.2)
Median levels of host markers detected in serum samples from children with TBM or no TBM (Inter-quartile range in parenthesis) and accuracies in the diagnosis of TBM. Cut-off values
and associated sensitivities and specificities were selected based on the Youden’s index. #values shown are in ng/ml, values for all other host markers are in pg/ml.
FIGURE 2 | Accuracy of the modified 7-marker serum protein biosignature (CRP, IFN-γ, IP-10, CFH, Apo-A1, SAA, and NCAM1) in the diagnosis of TBM. Scatter plot
showing the ability of the 7-marker signature to classify children as TBM or no TBM (A). ROC curve showing the accuracy of the 7-marker biosignature (B).
Red squares; children with TBM; blue circles: children with No TBM.
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FIGURE 3 | Representative plots showing the concentration of sVCAM-1 (A), CCL2/MCP-1 (B), IL-4 (C), TNF-a (G), CCL4/MIP-1ß (H) and CFD (I) detected in serum
samples from children with and without TBM and the ROC curves showing the accuracies of sVCAM-1 (D), CCL2/MCP-1 (E), IL-4 (F), TNF-a (J), CCL4/MIP-1ß (K)
and CFD (L) individually in the diagnosis of TBM. Error bars in the scatter-dot plots indicate the median and inter-quartile ranges. Representative plots for six analytes
with AUC ≥ 0.75 are shown. The accuracies of all host biomarkers evaluated in the study are shown in Supplementary Table 1.
IL-13, IL-21, IL-6, MCP-1, IP-10, MIG, GM-CSF, IL-1β, IL-
12/23p40, IL-17A, IL-4, and TNF-α were significantly higher
in CSF samples in comparison to serum samples, while the
levels of other markers including D-dimer, CC2, CC4b, CC5a,
adipsin, CF1, ADAMTS13, cathepsin D, ICAM-1, NCAM1,
sVCAM-1, PAI-1, Apo-CIII, CC3, CRP, A1AT, PEDF, SAP, and
MIP-4 were significantly higher in serum samples of all study
participants compared to CSF (Supplementary Table 2).
Only three proteins (CCL4, G-CSF, and I-309) showed
no difference between CSF and serum samples from
all children.
DISCUSSION
We assessed the usefulness of biomarkers comprising a
previously identified adult pulmonary TB 7-marker serum
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FIGURE 4 | Accuracy of the 3-marker serum biosignature (Complement factor D/adipsin, Ab42 and IL-10) in the diagnosis of TBM. Scatter plot showing the ability of
the 3-marker signature to classify children as TBM or no TBM (A). ROC curve showing the accuracy of the 3-marker biosignature (B). Red squares: children with
TBM; blue circles: children with No TBM.
protein biosignature (28) and modified versions where
transthyretin was replaced by NCAM1 and other host
biomarkers that have shown potential in the diagnosis of
TB disease in recent adult studies, as tools for diagnosis of
TBM in children. Although the modified adult 7-marker serum
protein biosignature showed potential as a diagnostic tool for
TBM in children, we identified a novel smaller TBM-specific
3-marker serum signature (adipsin, Aβ42, and IL-10), which
diagnosed childhood TBM with promising accuracy. It is
well-known that most of the poor outcomes resulting from being
diagnosed with TB are related to difficulties in the diagnosis of
the disease and/or delayed initiation of treatment, especially in
high burden settings. The currently available diagnostic tests
have several shortcomings, especially in young children and
in people presenting with extrapulmonary TB, including TBM
(13, 14). The diagnosis of TBM is particularly challenging in
resource-constrained areas owing to the expensive and invasive
modalities required in making a proper diagnosis. These tests
perform poorly individually (32, 33), with a combination of
several modalities including clinical presentation, CSF findings,
neuroimaging, evidence of extraneural TB, and where possible,
mycobacteriological confirmation, required for diagnosis (34).
Access to these tests requires admission to a tertiary hospital in
relatively well-resourced environments. Consequently, children
who do not have access these facilities, especially those in
resource-constrained, mainly rural settings, miss the opportunity
for early diagnosis. Children living in relatively better-resourced
areas such as in the Western Cape Province of South Africa still
present at the clinic an average of six times prior to eventual
proper diagnosis of TBM (20). These factors emphasize the
urgent need for new diagnostic tools in childhood TBM.
Host inflammatory protein biomarkers have been shown to
possess potential in the diagnosis of TB disease in both adults
and children in previous studies (25, 27, 28), including being
translated into field-friendly point-of-care tests (22, 23). In a
previous study done in our research group, a 3-marker CSF
biosignature (VEGF, IL-13, and LL-37) was identified which
showed potential as a tool for the diagnosis of TBM in children
(25). In a follow-up study, we validated this biosignature but
importantly, showed that replacement of two of the proteins in
this signature (IL-13 and LL-37) with new proteins (IFN-γ and
MPO) resulted in improved accuracy (29). Despite the potential
shown by these CSF-based biosignatures, collection of CSF, an
invasive procedure that requires lumbar puncture, is challenging
in resource-constrained areas. Given the promise shown by
blood-based inflammatory biosignatures in pulmonary TB, it is
important that similar approaches be assessed for the diagnosis
of TBM in children, given that blood will be easier to collect and
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the fact that blood-based tests may be easily converted into finger
prick-based tests as its currently being done in another project
(www.screen-tb.eu). In the current preliminary study, we have
shown proof of principle that blood-based protein biosignatures
may be useful in the diagnosis of childhood TBM. Given the
limited performance of the adult seven-marker signature in the
present study, tests that are developed on adult pulmonary TB
patients (e.g., the ScreenTB study) may not perform optimally
in children, especially those with TBM as demonstrated in this
study. We have however, identified a novel childhood TBM
specific 3-marker biosignature which may be considered for
further development into a blood-based point-of-care or bedside
test for childhood TBM after further validation studies.
A test that is based on blood-based biomarkers such as the
biosignature identified in the present study needs to be optimized
during future validation and development stages as a screening
test for TBM in children. Such a blood-based test is a high-
priority need, as identified in the published WHO target product
profiles for new diagnostics (35). Further development of such
a test into a finger prick blood-based assay will enable easier
implementation at the point-of-care or bedside, including in
resource-poor settings and may lead to significant reductions
in costs, unnecessary lumbar puncture procedures, and the
delays that are currently incurred in the diagnosis of TBM in
children (20) and consequently, a reduction in the morbidity
and mortality currently resulting from TBM. The more invasive
and expensive modalities currently being used in the diagnosis of
the disease could then only be applied in triaged children with
positive point-of-care tests. However, this will only be possible
after further validation experiments and incorporation of the
biomarkers into such point-of-care test platforms. It is well-
known that host inflammatory biomarker-based tests may not
be specific for TB, owing to the expression of the biomarkers
in other inflammatory conditions and cancer (28, 36). However,
it is believed that these specificity concerns may be addressed
through the combination of different host biomarkers as done
in the present study, with the resultant tests being implemented
as triage tests. Given the importance and urgency to commence
anti-tuberculous treatment in TBM, a diagnostic test requires
adequate sensitivity as well as specificity. A biomarker-based
diagnostic test for TBM should have as high sensitivity as possible
and preferably above 95% as recommended by the WHO to be
suitable as a triage test (35). Both the modified adult seven-
marker serum TB biosignature and our novel smaller TBM-
specific 3-marker serum signature had reasonable sensitivity and
specificity when compared to current individual tests for the
diagnosis of TBM, with the smaller serum protein signature
performing better. However, the accuracies of the two signatures
were below the limits specified for a triage test in theWHO target
product profiles for new tests (35). As this was largely a proof-
of-concept study, more work is required to ascertain whether
these signatures can be further optimized, for example, with new
markers, coupled with ascertaining the best clinical situations
where possible tools based on such proteins may be useful in the
TBM diagnostic landscape.
One of the proteins that formed part of our new TBM-specific
3-marker serum protein biosignature for samples correlate
with increased risk of a neurodegenerative disease known as
Alzheimer’s disease. However, these levels decrease as disease
progresses, supporting the concept of higher accumulation
of Aβ42 in neuronal deposits (37). In our study, levels of
serum Aβ42 did not show statistical difference between children
with TBM and those without TBM. However, these protein
contributed to the performance of our TBM-specific 3-marker
serum protein biosignature. The association of Aβ42 and
dementia in neurodegenerative disease, its decreased levels in
bacterial meningitis (38), and its contribution to our signature
might suggest its involvement in the pathology of TBM. IL-
10 (which also formed part of signature) is a well-known anti-
inflammatory and regulatory cytokine. The production of IL-
10 is highly increased in healthy human neonates, making this
population to be susceptible to TBM (39). Similarly, serum levels
of IL-10 were higher in children without TBM in our study.
Adipsin/complement factor D play a role as a regulator in the
activation of the alternative complement pathway (40).
The main limitation of the current study was the small sample
size, especially small number of individuals with confirmed
TBM (n = 3). However, as this preliminary study included
only children with signs and symptoms and who were referred
after strong suspicion of TBM, the design of the study was
relatively strong. Although the number of participants enrolled
into the study is consistent with patient numbers that were
described in multiple previous studies, there is a need to
further assess the biomarkers that showed potential in this
preliminary study in larger numbers of study participants with
suspectedmeningitis. Such future studies should include children
who are HIV infected, and more individuals with confirmed
TBM as well as confirmed alternative meningitis. This would
allow proper validation of the promising signatures by using
training and test sets of samples. The authors of the current
manuscript acknowledge the importance of correction of data
for multiple comparisons during statistical analysis. This was not
done in the in the current study because it was a small, proof-
of-concept study intended to ascertain whether adult-derived
serum biomarkers have potential to be useful in children. More
rigorous statistical analysis is recommended in future, well-
powered studies. As HIV-infected individuals and smaller infants
may have diminished immune responses as compared to HIV-
negative older children and adults (41), it may be worthy to
evaluate the effect of HIV status as well as age group (smaller
infants vs. older children) on the performance of the biomarkers
in future, larger studies. The use of different biosignatures as tools
for triaging children enrolled at lower levels of the healthcare
system into those with potentially serious conditions such as
meningitis, and other less concerning conditions still needs to be
investigated andwas not the aim of the present preliminary study.
In conclusion, we have shown that a modified version of a
previously identified adult 7-marker serum protein biosignature
(CRP, SAA, complement factor H, IFN-γ, IP-10, Apo AI, and
NCAM1, in place of transthyretin) may be useful in the diagnosis
of TBM in children. However, the performance of this modified
signature was reduced, compared to what was reported in
adults with pulmonary TB, albeit, with transthyretin in place of
NCAM1 in the adult study. Furthermore, we identified a smaller
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childhood TBM specific 3-marker biosignature (adipsin, Aβ42,
and IL-10) with potential as a diagnostic tool for childhood
TBM. As this was a largely proof-of-concept study, intended to
ascertain the utility of serum host protein biomarkers in the
diagnosis of childhood TBM, our findings are preliminary and
require validation in larger studies.
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